Antimicrobial Resistance MS Detection Patents: Leaders & Trends 2026
- One assignee dominates the leaderboard. the leader holds 29 of the ranked families against a fifth-place count of 2 and a tenth-place count of 1 — a steep drop-off rather than a gradual taper.
- Filing has cooled from a 2018 peak of 12. the tracked growth window shows a -100% swing from 2021 (6 filings) to 2024 (0), the last year publication lag lets us treat as complete.
- Claims cluster tightly on enzymatic detection. C12Q covers 92.7% of the 55 records in scope, while combinatorial-library claims under C40B still reach 29.1% — an unusual amount of library-based claiming for this field.
Filing growth compares 2021 (6 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
This landscape tracks patent families addressing mass spectrometry and related molecular methods for detecting antimicrobial resistance — spanning carbapenemase hydrolysis assays, resistance-marker identification, peak-shift readouts and phenotypic confirmation workflows tied to breakpoint correlation. The scope draws on 55 published records filed or published between 2015 and mid-2026, indexed by IPC subclass, receiving office, assignee and citation count.
Coverage stretches across diagnostics instrumentation, enzyme and nucleic-acid assay chemistry, and the informatics layer that turns a hydrolysis signal into a clinical resistance call. Because publication trails filing by roughly 18 months, the most recent one to two years in any trend understate real filing activity and should be read as provisional.
Filing trend and technology composition
The record set spans 2015 through mid-2026, with receiving-office activity concentrated in the United States, Europe and the WIPO PCT channel, followed by a smaller but active tail across Hong Kong, India and Canada.
Filing trend, 2017-2026
Filings rose from 4 in 2017 to a peak of 12 in 2018, then declined; the tracked growth span shows 2021 at 6 falling to 0 by 2024, a -100% move over three years. 2025 and 2026 are still filling in under normal publication lag and should not be read as a continued decline.
IPC subclass composition
C12Q (measuring/testing involving enzymes or DNA) touches 92.7% of the 55 records, making it the default classification for this whole technology. G01N (material analysis) sits at 38.2% and C40B (combinatorial libraries) at 29.1%, with G06F (digital data processing), C12M (bioreactors), G16H (health informatics), C12N (microorganisms) and A61K (medicinal preparations) forming a smaller supporting tier. Since a single record can carry multiple IPC codes, these shares sum to well over 100% of the record total.
Shares are the percentage of the 55 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Mass Spectrometry Detection of Antimicrobial Resistance with Eureka
This page is one run against one query. Ask Eureka your own question about mass spectrometry detection of antimicrobial resistance and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in this landscape
Integrated Diagnostic Instrument
A pathogen detection device includes a pathogen detector circuit configured to detect a target analyte in a patient sample, determine the presence of a pathogen from the target analyte, and generate a detection result including the identity of the pathogen and resistance genes, if any. A decision support generator circuit then applies user-configurable rules to that detection result to produce decision support information for the detection report.Filed by Roche Molecular Systems, published 2019-12-05 (US20190369126A1).
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20160231324A1 | Encapsulated sensors and sensing systems for bioassays and diagnostics and methods for making and using them | 188 |
| 2 | WO2015048173A2 | Encapsulated sensors and sensing systems for bioassays and diagnostics and methods for making and using them | 74 |
| 3 | WO2016187234A1 | Compositions and methods for enriching populations of nucleic acids | 44 |
| 4 | US20170016048A1 | Compositions and methods for enriching populations of nucleic acids | 41 |
| 5 | US20190369126A1 | Integrated Diagnostic Instrument | 12 |
| 6 | US11111520B2 | Compositions and methods for enriching populations of nucleic acids | 11 |
| 7 | WO2015048173A3 | Encapsulated sensors and sensing systems for bioassays and diagnostics and methods for making and using them | 5 |
| 8 | US10935561B2 | Integrated diagnostic instrument | 3 |
| 9 | EP3597768B1 | Method and system for rapidly testing antimicrobial susceptibility | 2 |
| 10 | WO2010089547A1 | Assay products, devices and method (VRE) | 2 |
Citation counts reflect influence inside this searched corpus and skew toward older filings; treat them as a signal of prior influence, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once families rather than raw counts are the unit of comparison.
One assignee sets the claim baseline
The leading assignee holds 29 of the ranked families, while fifth place holds only 2 and tenth place holds 1. That gap means most competitive activity in this space is really a conversation with one incumbent's portfolio, not a broad field of comparable filers.
Filing has pulled back from its 2018 high
Activity peaked at 12 filings in 2018 and the tracked growth window shows 2021's 6 filings falling to 0 by 2024, a -100% change. Treat 2025-2026 figures as incomplete rather than as confirmation the field has gone quiet.
Enzyme/DNA measurement is the default claim class
C12Q covers the large majority of records, but a meaningful secondary cluster sits in C40B combinatorial libraries at 29.1% — a heavier library-claiming presence than is typical for a diagnostics niche this size.
Filing is split between US and European routes
The United States (12) and the European Patent Office (10) lead receiving-office counts, with the WIPO PCT channel (6) used for broader coverage and smaller but active filings into Hong Kong, India and Canada.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to mass spectrometry detection of antimicrobial resistance, with the prior art for and against each one.
Who holds the claims
The ranking returned by the data endpoint lists 16 companies, counted in patent families — not a top-50 or top-100 cut, simply the full set the search returns.
A single incumbent anchors the field
The top-ranked assignee's family count is an order of magnitude above the rest of the field, consistent with an early, broad instrumentation and assay filing programme that later entrants have had to file around rather than compete with directly.
Most other filers hold one or two families
Beyond the leader, filing counts drop quickly: fifth place holds 2 families and tenth place holds 1. This pattern points to narrow, defensive filings rather than sustained portfolio-building by most named organisations here.
Co-filing is limited and individually driven
Ten co-assignee pairs appear in the dataset, with the strongest recurring links involving individual named inventors rather than corporate joint ventures — collaborative filing is present but not a structural feature of this landscape.
| Assignee | Recent year | YoY |
|---|---|---|
| Karius Inc | 0 | -100% |
| Bacteromic Sp. z o.o. | 0 | — |
| The Regents of the University of California | 0 | — |
| Roche Diagnostics GmbH | 0 | — |
| VAISHNAVI NEWASKAR | 0 | -100% |
| SEAMAN PAUL F | 0 | — |
| Q Chip Ltd | 0 | — |
| NIDHI YADAV | 0 | -100% |
Where to take this analysis
The dataset points to a concentrated core and a thinner set of adjacent claim areas; the next step is usually to test freedom-to-operate against the leader's family and to scope claims around the under-claimed branches.
Map freedom-to-operate against the leading portfolio
With one assignee holding 29 of the ranked families, a targeted claim chart against that portfolio will show more than a broad landscape scan across all 16 ranked companies.
Run a freedom-to-operate checkDraft around the under-claimed branches
Peak-shift calibration, breakpoint-correlation software and incubation-time optimisation show thinner filing density than the core C12Q cluster and may support a cleaner first claim.
Explore white space in EurekaCommon questions on this landscape
This landscape identifies 55 published patent families addressing detection of antimicrobial resistance through carbapenemase hydrolysis assays, resistance-marker identification, peak-shift readouts and phenotypic confirmation workflows. Most of these records classify under IPC subclass C12Q, covering measuring and testing methods involving enzymes or DNA, with a secondary cluster in G01N material analysis and C40B combinatorial libraries. The records span filings and publications from 2015 through mid-2026, filed across the United States, Europe, the WIPO PCT channel, Hong Kong, India and Canada.
The assignee ranking for this dataset lists 16 companies, and it is heavily concentrated at the top: the leading assignee holds 29 of the ranked families, compared with 2 at fifth place and 1 at tenth. That gap means a small number of organisations, rather than a broad competitive field, hold most of the enforceable claim scope in this space. Anyone evaluating freedom-to-operate should prioritise checking the leader's portfolio before surveying the rest of the ranking.
Filing peaked at 12 in 2018 and the most recent complete growth window shows a decline from 6 filings in 2021 to 0 by 2024, a -100% change over that span. Because patent publication lags filing by roughly 18 months, the 2025 and 2026 figures in this dataset are still incomplete and should not be read as confirmation that interest is falling — they simply have not caught up yet. Treat 2024 as the last year with a reliable count for trend purposes.
US20190369126A1, an Integrated Diagnostic Instrument filing assigned to Roche Molecular Systems, claims a pathogen detector circuit that identifies both a pathogen and any associated resistance genes from a patient sample, paired with a decision support generator that applies configurable logic rules to produce a detection report. That combination — detection plus rule-based decision support in a single integrated instrument claim — is the part most likely to constrain competing instrument designs. Assay chemistry or software-only implementations that do not bundle both elements into one circuit-level claim have more room to operate around it.
Relative to the dense C12Q enzyme and DNA measurement cluster that covers 92.7% of the 55 records, several adjacent areas show much thinner filing: peak-shift calibration methods specific to MALDI-TOF resistance calls, breakpoint-correlation software layers, multiplexed carbapenemase hydrolysis panels, and incubation-time optimisation for phenotypic confirmation. These branches sit close to the core technology but are not yet heavily claimed, which typically means more room for a clean first-filed claim. Any white-space claim should still be checked against the leading assignee's broader portfolio, since a thin count in a subclass does not guarantee the space is fully open.
Research Mass Spectrometry Detection of Antimicrobial Resistance in depth with Eureka
Go past this page: query the whole mass spectrometry detection of antimicrobial resistance corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.